Strategic Acquisition to Expand Governance, Risk, and Compliance Capabilities
MediSpend, a global leader in technology solutions for the life sciences industry, has announced the acquisition of Real Life Sciences (RLS), a renowned provider of advanced anonymization and redaction solutions for clinical trial data. This marks MediSpend’s second acquisition in under a year, underscoring its commitment to expanding its expertise and capabilities in the Governance, Risk, and Compliance (GRC) space.
RLS’s flagship platform, RLS Protect, specializes in safeguarding participant privacy and intellectual property while enabling life sciences organizations to meet complex regulatory requirements for clinical trial disclosures. This acquisition strengthens MediSpend’s ability to assist life sciences companies and contract research organizations (CROs) in navigating global regulatory demands while maintaining transparency and confidentiality.
RLS Protect: Elevating Data Anonymization and Redaction
Real Life Sciences’ solutions are centered on RLS Protect, a proprietary platform offering advanced tools to ensure data privacy. The platform includes:
- Anonymization: Utilizing quantitative risk modeling and natural language processing to protect participant privacy in shared clinical data.
- Redaction: Tools to redact sensitive and commercially confidential information in compliance with global standards.
- Voluntary Data Sharing: Streamlining the secure sharing of anonymized clinical trial data for internal and external research purposes.
- Anonymization Services: Expert-driven support for timely anonymization and redaction projects adhering to health authority guidelines.
Leigh Powell, Executive Chairman of MediSpend, praised RLS’s innovative solutions, stating, “Real Life Sciences’ technology aligns seamlessly with MediSpend’s mission to empower life sciences companies with tools for growth, compliance, and transparency. This acquisition enhances our ability to serve clients across the R&D spectrum and support their compliance with evolving global regulations.”
Transforming Compliance and Transparency in Life Sciences
RLS’s proven track record in addressing regulatory requirements from major bodies, including the EMA, FDA, and Health Canada, positions MediSpend as a stronger partner for life sciences companies. The acquisition expands MediSpend’s portfolio to include compliance solutions for both commercial and R&D operations, helping clients comprehensively manage regulatory challenges.
Elliot Zimmerman, CEO of Real Life Sciences, emphasized the transformative nature of the partnership, stating, “Joining MediSpend allows us to enhance our solutions for life sciences organizations navigating global requirements for clinical transparency, data sharing, and participant privacy. Together, we’re uniquely positioned to deliver innovative solutions across the industry.”
About MediSpend and Real Life Sciences
Headquartered in Portsmouth, N.H., with offices in the U.S. and the Netherlands, MediSpend provides top-tier compliance solutions for global pharmaceutical, medical device, and biotech companies. Real Life Sciences, based on its flagship platform RLS Protect, is a trusted provider of anonymization and redaction solutions for clinical data, ensuring compliance while protecting sensitive information. The transaction was facilitated by Madison Park Group, the exclusive financial advisor to RLS.
Through this acquisition, MediSpend reinforces its leadership in compliance technology, empowering life sciences companies to thrive in a complex regulatory landscape.
